NIKKEI 225
28,257.25 -76.27 (-0.27%) HANG SENG
24,139.85 -78.18 (-0.32%) CRUDE OIL
85.42 +1.60 (+1.91%) GOLD FUTURES
1,815.70 -0.80 (-0.04%) DOW
35,911.81 -201.79 (-0.56%) BTC-GBP
30,994.26 -539.40 (-1.71%)
MorphoSys AG (MOR.DE)
- EQS Group
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys AG / Key word(s): Conference10.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 10, 2022MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare ConferenceMorphoSys AG (FSE: MOR; NASDAQ: MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at 5:15 p.m. EST.Li
- EQS Group
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-News: MorphoSys AG / Key word(s): Forecast07.01.2022 / 07:59 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 07, 2022MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million (€ 66.9 million)- Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 millionMorphoSys AG (FSE: MOR; NASDAQ: MOR) today rep
- EQS Group
MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
MorphoSys AG / Key word(s): ForecastMorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance07-Jan-2022 / 07:55 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014Planegg/Munich, Germany, J
